Lexeo Therapeutics is a clinical-stage gene therapy company focused on cardiovascular diseases. Lexeo's approach is to treat the genetic root causes of serious heart conditions by delivering functional copies of defective genes directly to heart muscle cells using adeno-associated virus (AAV) vectors. Lexeo has no approved products and no revenue today. Its two most advanced programs are in Phase 1/2 trials: LX2006 targets Friedreich ataxia cardiomyopathy by delivering a functional FXN gene, and LX2020 targets PKP2-arrhythmogenic cardiomyopathy by restoring the structural integrity of cardiac desmosomes. Both programs address rare diseases with no approved treatments. LX2006 holds Breakthrough Therapy, RMAT, and several other FDA designations, and Lexeo plans to initiate a pivotal trial in the first half of 2026. Earlier-stage programs include LX2021 for DSP cardiomyopathy and LX2022 for TNNI3-associated hypertrophic cardiomyopathy, both in preclinical development. If approved, Lexeo's therapies would be priced as one-time infusions targeting small rare patient populations. Lexeo licenses core IP from Cornell and UCSD, and owes milestone payments and royalties to those institutions, as well as to Adverum, on any future net sales. Lexeo funds operations through equity financing and relies on its proprietary Sf9 baculovirus manufacturing process, which it argues delivers higher yields and lower costs than traditional methods.